Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, parallel, open-label, positive-controlled Phase 2
clinical trial, which aims to evaluate the early bactericidal activity, safety and
tolerability of WX-081 in patients with drug-naive&susceptible and drug-resistant
tuberculosis. Also the efficacy of WX-081 will be explored in participants with
drug-resistant tuberculosis.